Oslo, 29 October 2025 – Reference is made to the previous stock exchange announcements made in connection with the combination of BerGenBio ...
Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the present...
Bergen, Norway and Oslo, Norway, 24 October 2025 – Reference is made to the joint stock exchange announcement on 30 June 2025 by BerGenBio A...
New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression Oncoinvent ASA, a clinical-stage radiopharmaceutical co...
Oslo, 17 September 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by BerGenBio ASA (the "Company") an...
Oslo, 17 September 2025: Reference is made to the stock exchange announcement published by BerGenBio ASA (the "Company") on 5 August 2025 re...
Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and Oncoinvent ASA, a clinic...
Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximi...
Oslo, Norway, 4 August 2024 – Reference is made to the joint stock exchange announcement made on 30 June 2025 by Oncoinvent ASA ("Oncoinvent...
An extraordinary general meeting in Oncoinvent ASA will be held on 4.
Bergen, Norway and Oslo, Norway, 30 June 2025: BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with prefere...
Bergen, Norway and Oslo, Norway, 30 June 2025 – BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("...
